Saturday

23rd Mar 2019

Opinion

Why are our medicines so expensive?

  • 'Austerity politics mean people in Europe are also facing a growing treatment access gap' (Photo: isobrown)

In the lead-up to an inter ministerial meeting between EU and India next week, European trade negotiators continue to pressure India and other developing countries to accept so-called “free trade” agreements that favour patent monopolies, high medicines prices, and the interests of the pharmaceutical industry.

Instead, the EU should be promoting open innovation and should work to bring down the prices of essential medicines, both abroad and within its borders.

Read and decide

Join EUobserver today

Support quality EU news

Get instant access to all articles — and 18 year's of archives. 30 days free trial.

... or join as a group

For Europeans who have never had to worry about access to health care or medicines, it comes as a shock that the downward spiral of financial crisis and ensuing austerity politics have put at risk our once sacrosanct right to access affordable, quality health care.

Reading the agonizing stories of cancer patients in Greece who can no longer afford the medicines that keep them alive, or immigrants in Spain who no longer get costly AIDS cocktails because their health care is being revoked, it is clear we have our priorities wrong.

But why are our medicines so expensive?

For decades, Western countries have relied on an innovation model that provides generous incentives to pharmaceutical companies to develop and test medicines. Public funds support much of the early research for new medicines, and companies that bring new drugs to market receive tax credits and patents that let them charge monopoly prices and make high profits.

For a long time, wealthy countries with comprehensive health insurance coverage considered expensive medicines an acceptable price to pay for medical innovation and a booming pharmaceutical sector, since no one had to pay the full cost of medicines out-of-pocket.

Now that austerity measures are shifting these high cost to patients, however, we must ask - what is the point of having medical innovation if we cannot afford the therapies it delivers?

This, of course, is the situation that people living in low and middle income countries have confronted all along. For example, the price of life-saving hepatitis C medicines, sold under monopoly pricing by Merck and Roche can easily cost €15,000 per treatment.

Similarly, Novartis has maintained a global price of around €2,000 per month for its breakthrough cancer drug Glivec.

Treatment access gap

It is no surprise that virtually no one outside of rich countries can access these medicines. Now, austerity politics in the EU mean that poor, unemployed, and otherwise disadvantaged groups in Europe are also facing a growing treatment access gap.

We know from other countries that most medicines can be produced at a fraction of the price they cost in Europe. For instance, a generic version of Glivec is available in India at around €120 per month, much to the discontent of Novartis, who challenged India’s patent law in court to maintain its grip on profits.

Last week, after a seven year legal battle, patients won a landmark victory when India’s Supreme Court upheld the legality of the generic, thus safeguarding India’s role as a global hub for generic medicines.

Yet instead of finding ways to reduce the price of medicines, the European Commission’ is pursuing deals that would further restrict countries’ abilities to speed up generic availability and effective price competition. Following what Commissioner Karel De Gucht calls an “ambitious European free trade agenda”, they seek to promote the exportation of Europe's pharmaceutical products at high prices, favouring pharma companies over the health of the people.

EU India trade talks

In protracted closed door negotiations for an EU-India Free Trade Agreement, the Directorate General for Trade and corporate advisors continue to pressure India to accept provisions that undermine public health safeguards and favour corporate interests.

These include enhanced protection of patents and clinical data, which are known to delay entry of generic medicines into the market. Patients and health activists in countries such as Jordan and Guatemala have learnt the hard way that access to medicines is among the first issues to be compromised in such trade negotiations, seeing medicines prices soar once the agreements were signed.

In effect, the EU is pressuring India to make concessions that will undermine the health of millions of people worldwide, for whom India is their affordable pharmacy.

Rather than exporting its unsustainable model of patent-driven innovation and expensive medicines, Europe should stay focused on one of its greatest traditions - accessible health care for all.

While it could learn lessons from India about reducing medicine prices, Europe is ideally positioned to lead the way towards novel, open, and collaborative models of medical innovation that will ensure new medicines meet our health needs at prices people can afford.

We know this is possible. Even the head of GlaxoSmithKline Andrew Witty admits that the alleged $1 billion price tag for drug development - the chief excuse for high medicines prices - is “one of the great myths of the industry.”

In this age of financial difficulties, expensive medicines need not be.

The writer is the director of the Open Society Public Health Programme’s Access to Essential Medicines Initiative.

Focus

EU alternative-medicine safety rules will slim down access

Measures forcing the purveyors of alternative medicines to prove they are safe and that they have a long track-record of people believing they work will cut the number of herbal remedies and traditional Chinese medical products on the European market from 1 May.

Thousands march in India against EU trade deal

Thousands of HIV-positive protesters took to the streets in downtown New Delhi on Wednesday, concerned that an imminent EU-India free trade agreement will end the production of affordable life-prolonging drugs.

News in Brief

  1. EU leaders at summit demand more effort on disinformation
  2. Report: Corbyn to meet May on Monday for Brexit talks
  3. Petition against Brexit attracts 2.4m signatures
  4. Study: Brexit to cost EU citizens up to €40bn annually
  5. NGOs demand France halt Saudi arm sales
  6. Report: Germany against EU net-zero emissions target
  7. Former top EU official takes job at law firm
  8. Draft text of EU summit has Brexit extension until 22 May

Italy should capitalise on Brexit

Now that the UK is leaving, Italy can, and should, step up. It is the third largest country and economy in the EU. Spain and Poland follow, but they are significantly smaller economically and population-wise.

The Magnitsky Act - and its name

It is disappointing that so many MEPs in the Socialist and Green group caved in to Russian interests, in fear of challenging a plutocratic regime, by saying 'no' to naming the Magnitsky legislation by its rightful name: Magnitsky.

Stakeholders' Highlights

  1. Nordic Council of MinistersNew campaign: spot, capture and share Traces of North
  2. Nordic Council of MinistersLeading Nordic candidates go head-to-head in EU election debate
  3. Nordic Council of MinistersNew Secretary General: Nordic co-operation must benefit everybody
  4. Platform for Peace and JusticeMEP Kati Piri: “Our red line on Turkey has been crossed”
  5. UNICEF2018 deadliest year yet for children in Syria as war enters 9th year
  6. Nordic Council of MinistersNordic commitment to driving global gender equality
  7. International Partnership for Human RightsMeet your defender: Rasul Jafarov leading human rights defender from Azerbaijan
  8. UNICEFUNICEF Hosts MEPs in Jordan Ahead of Brussels Conference on the Future of Syria
  9. Nordic Council of MinistersNordic talks on parental leave at the UN
  10. International Partnership for Human RightsTrial of Chechen prisoner of conscience and human rights activist Oyub Titiev continues.
  11. Nordic Council of MinistersNordic food policy inspires India to be a sustainable superpower
  12. Nordic Council of MinistersMilestone for Nordic-Baltic e-ID

Latest News

  1. Italy takes China's new Silk Road to the heart of Europe
  2. What EU leaders agreed on climate - and what they mean
  3. Copyright and (another) new Brexit vote This WEEK
  4. EU avoids Brexit crash, sets new date for 12 April
  5. Campaigning commissioners blur the lines
  6. Slovakia puts squeeze on free press ahead of election
  7. EPP suspends Orban's Fidesz party
  8. Macron is confusing rigidity with strength

Stakeholders' Highlights

  1. Counter BalanceEU bank urged to free itself from fossil fuels and take climate leadership
  2. Intercultural Dialogue PlatformRoundtable: Muslim Heresy and the Politics of Human Rights, Dr. Matthew J. Nelson
  3. Platform for Peace and JusticeTurkey suffering from the lack of the rule of law
  4. UNESDASoft Drinks Europe welcomes Tim Brett as its new president
  5. Nordic Council of MinistersNordic ministers take the lead in combatting climate change
  6. Counter BalanceEuropean Parliament takes incoherent steps on climate in future EU investments
  7. International Partnership For Human RightsKyrgyz authorities have to immediately release human rights defender Azimjon Askarov
  8. Nordic Council of MinistersSeminar on disability and user involvement
  9. Nordic Council of MinistersInternational appetite for Nordic food policies
  10. Nordic Council of MinistersNew Nordic Innovation House in Hong Kong
  11. Nordic Council of MinistersNordic Region has chance to become world leader when it comes to start-ups
  12. Nordic Council of MinistersTheresa May: “We will not be turning our backs on the Nordic region”

Join EUobserver

Support quality EU news

Join us